SK287066B6 - Farmaceutická formulácia s predĺženým uvoľňovaním a spôsob jej prípravy - Google Patents
Farmaceutická formulácia s predĺženým uvoľňovaním a spôsob jej prípravy Download PDFInfo
- Publication number
- SK287066B6 SK287066B6 SK355-2003A SK3552003A SK287066B6 SK 287066 B6 SK287066 B6 SK 287066B6 SK 3552003 A SK3552003 A SK 3552003A SK 287066 B6 SK287066 B6 SK 287066B6
- Authority
- SK
- Slovakia
- Prior art keywords
- formulation
- hpmc
- formulation according
- active
- release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL1016295 | 2000-09-29 | ||
| EP00203381 | 2000-09-29 | ||
| PCT/EP2001/011285 WO2002026214A1 (en) | 2000-09-29 | 2001-09-28 | Ion-strength independent sustained release pharmaceutical formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK3552003A3 SK3552003A3 (en) | 2003-10-07 |
| SK287066B6 true SK287066B6 (sk) | 2009-11-05 |
Family
ID=26072736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK355-2003A SK287066B6 (sk) | 2000-09-29 | 2001-09-28 | Farmaceutická formulácia s predĺženým uvoľňovaním a spôsob jej prípravy |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8034379B2 (de) |
| EP (1) | EP1345595B1 (de) |
| JP (1) | JP5049450B2 (de) |
| KR (1) | KR100833469B1 (de) |
| CN (1) | CN1466451B (de) |
| AT (1) | ATE361060T1 (de) |
| AU (2) | AU2357202A (de) |
| BR (1) | BR0114272A (de) |
| CA (1) | CA2426666A1 (de) |
| CZ (1) | CZ299411B6 (de) |
| DE (1) | DE60128263T2 (de) |
| DK (1) | DK1345595T3 (de) |
| DZ (1) | DZ3473A1 (de) |
| ES (1) | ES2284709T3 (de) |
| HK (1) | HK1060691A1 (de) |
| HU (1) | HUP0301177A3 (de) |
| IL (2) | IL154731A0 (de) |
| MX (1) | MXPA03002769A (de) |
| NO (1) | NO20031409D0 (de) |
| NZ (1) | NZ524641A (de) |
| PL (1) | PL203217B1 (de) |
| PT (1) | PT1345595E (de) |
| RU (1) | RU2285519C2 (de) |
| SI (1) | SI1345595T1 (de) |
| SK (1) | SK287066B6 (de) |
| WO (1) | WO2002026214A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070099931A1 (en) * | 2004-03-19 | 2007-05-03 | Wyeth | Pharmaceutical dosage forms and compositions |
| BRPI0511079A (pt) | 2004-05-11 | 2007-12-26 | Emotional Brain Bv | usos de uma combinação de um inibidor de pde5 e testosterona ou de um seu análogo, e de testosterona ou de um seu análogo, formulação farmacêutica, e, kit de partes |
| US20060003003A1 (en) * | 2004-06-28 | 2006-01-05 | Bakker Johan A | Oral sustained release formulation of tedisamil with gastric retention properties |
| AR049936A1 (es) * | 2004-06-28 | 2006-09-13 | Solvay Pharm Bv | Formulacion oral de liberacion sostenida de tedisamil con propiedades de retencion gastrica |
| AU2005256653B2 (en) * | 2004-06-28 | 2010-10-14 | Solvay Pharmaceuticals B.V. | Oral sustained release formulation of tedisamil with gastric retention properties |
| JP2006143598A (ja) * | 2004-11-16 | 2006-06-08 | Nichi-Iko Pharmaceutical Co Ltd | 経時的な変色を抑制した医薬組成物 |
| TW200800198A (en) * | 2005-09-09 | 2008-01-01 | Wyeth Corp | Pharmaceutical dosage forms and compositions |
| EP1790343A1 (de) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau |
| US7863275B2 (en) * | 2006-10-30 | 2011-01-04 | The Board Of Regents Of The University Of Texas System | Uses of tetrahydrobiopterin and derivatives thereof |
| US8669258B2 (en) | 2006-10-30 | 2014-03-11 | The Board Of Regents Of The University Of Texas System | Treatment for gastroparesis using sepiapterin |
| EP1925307A1 (de) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion |
| US7965077B2 (en) * | 2008-05-08 | 2011-06-21 | Everspin Technologies, Inc. | Two-axis magnetic field sensor with multiple pinning directions |
| PL2395840T3 (pl) | 2009-02-13 | 2020-09-07 | Romark Laboratories, L.C. | Preparaty farmaceutyczne nitazoksanidu o kontrolowanym uwalnianiu |
| WO2013157833A1 (ko) * | 2012-04-18 | 2013-10-24 | 서울대학교산학협력단 | 베타-차단제를 유효성분으로 포함하는 비만, 비만으로 인한 대사성 질환 및 골감소증 예방, 개선 또는 치료용 조성물 |
| KR102116495B1 (ko) * | 2013-08-28 | 2020-06-03 | 삼성디스플레이 주식회사 | 축합환 화합물을 포함하는 유기 전계 발광 소자 |
| WO2016020901A1 (en) | 2014-08-07 | 2016-02-11 | Acerta Pharma B.V. | Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate |
| CN104352471A (zh) * | 2014-11-21 | 2015-02-18 | 哈尔滨圣吉药业股份有限公司 | 一种马来酸氟伏沙明缓释片及其制备方法 |
| IL308650A (en) | 2017-06-21 | 2024-01-01 | Minerva Neurosciences Inc | Stomach-resistant controlled-release oral dosage forms |
| TWI841545B (zh) * | 2018-12-12 | 2024-05-11 | 日商田邊三菱製藥股份有限公司 | 耐胃性控制釋放經口劑型 |
| US12016851B2 (en) * | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| FR2588188B1 (fr) * | 1985-10-04 | 1988-01-08 | Delalande Sa | Comprime de sel(s) hydrosoluble(s) de cinepazide a liberation programmee et son procede de preparation |
| US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
| US5387419A (en) * | 1988-03-31 | 1995-02-07 | The University Of Michigan | System for controlled release of antiarrhythmic agents |
| US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
| DE4139763A1 (de) * | 1991-12-03 | 1993-06-09 | Kali-Chemie Pharma Gmbh, 3000 Hannover, De | Kristalline fumarsaure salze von 9,9-alkylen-3,7-diazabicyclononan-verbindungen und diese verbindungen enthaltende arzneimittel |
| ZA959221B (en) | 1994-11-02 | 1997-04-30 | Janssen Pharmaceutica Nv | Cisapride extended release |
| CN1162263A (zh) * | 1994-11-02 | 1997-10-15 | 詹森药业有限公司 | 西沙必利的缓释口服组合物 |
| WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
| CA2216215A1 (en) | 1997-04-05 | 1998-10-05 | Isa Odidi | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity |
| CA2290624C (en) * | 1997-06-06 | 2006-12-05 | John W. Shell | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US5948440A (en) | 1997-12-17 | 1999-09-07 | Ranbaxy Laboratories Limited | Modified release matrix formulation of cefaclor and cephalexin |
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| EP1086063A4 (de) * | 1998-06-08 | 2001-03-28 | Advanced Medicine Inc | Kaliumkanal wirkstoffe und deren verwendung |
| PT1121104E (pt) * | 1998-10-01 | 2005-05-31 | Novartis Ag | Novas formulacoes orais de libertacao controlada |
| CO5140079A1 (es) * | 1998-10-14 | 2002-03-22 | Novartis Ag | Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo |
| JP2004518664A (ja) | 2000-12-27 | 2004-06-24 | ジェンザイム・コーポレーション | 抗不整脈剤の調節された放出 |
-
2001
- 2001-09-28 MX MXPA03002769A patent/MXPA03002769A/es active IP Right Grant
- 2001-09-28 CA CA002426666A patent/CA2426666A1/en not_active Withdrawn
- 2001-09-28 EP EP01985673A patent/EP1345595B1/de not_active Expired - Lifetime
- 2001-09-28 US US10/381,714 patent/US8034379B2/en not_active Expired - Fee Related
- 2001-09-28 AU AU2357202A patent/AU2357202A/xx active Pending
- 2001-09-28 KR KR1020037004552A patent/KR100833469B1/ko active IP Right Grant
- 2001-09-28 CZ CZ20030898A patent/CZ299411B6/cs not_active IP Right Cessation
- 2001-09-28 PL PL360670A patent/PL203217B1/pl unknown
- 2001-09-28 HU HU0301177A patent/HUP0301177A3/hu unknown
- 2001-09-28 CN CN01816515XA patent/CN1466451B/zh not_active Expired - Fee Related
- 2001-09-28 WO PCT/EP2001/011285 patent/WO2002026214A1/en active IP Right Grant
- 2001-09-28 SI SI200130732T patent/SI1345595T1/sl unknown
- 2001-09-28 RU RU2003112459/15A patent/RU2285519C2/ru not_active IP Right Cessation
- 2001-09-28 AT AT01985673T patent/ATE361060T1/de active
- 2001-09-28 SK SK355-2003A patent/SK287066B6/sk not_active IP Right Cessation
- 2001-09-28 BR BR0114272-0A patent/BR0114272A/pt not_active Application Discontinuation
- 2001-09-28 JP JP2002530044A patent/JP5049450B2/ja not_active Expired - Fee Related
- 2001-09-28 ES ES01985673T patent/ES2284709T3/es not_active Expired - Lifetime
- 2001-09-28 PT PT01985673T patent/PT1345595E/pt unknown
- 2001-09-28 NZ NZ524641A patent/NZ524641A/en not_active IP Right Cessation
- 2001-09-28 DE DE60128263T patent/DE60128263T2/de not_active Expired - Lifetime
- 2001-09-28 DZ DZ013473A patent/DZ3473A1/fr active
- 2001-09-28 AU AU2002223572A patent/AU2002223572B2/en not_active Ceased
- 2001-09-28 DK DK01985673T patent/DK1345595T3/da active
- 2001-09-28 IL IL15473101A patent/IL154731A0/xx active IP Right Grant
-
2003
- 2003-03-04 IL IL154731A patent/IL154731A/en not_active IP Right Cessation
- 2003-03-27 NO NO20031409A patent/NO20031409D0/no not_active Application Discontinuation
-
2004
- 2004-05-14 HK HK04103387.1A patent/HK1060691A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK287066B6 (sk) | Farmaceutická formulácia s predĺženým uvoľňovaním a spôsob jej prípravy | |
| AU2002223572A1 (en) | Ion-strength independent sustained release pharmaceutical formulation | |
| EP2068835A2 (de) | Imatinib-zusammensetzungen | |
| SK4299A3 (en) | A tablet contaning methanesulfonate of trovafloxacin | |
| EP2804588B1 (de) | Verfahren zur herstellung von cinacalcetzusammensetzungen zur direkttablettierung | |
| EP1928425B1 (de) | Pharmazeutische Formulierung enthaltend Fluvastatin | |
| EP2471519B1 (de) | Formulierung aus carvedilol mit gesteuerter freisetzung | |
| EP3154525B1 (de) | Pharmazeutische zusammensetzung mit einem triazolantifungizid und verfahren zur herstellung davon | |
| KR101941511B1 (ko) | 분자량분포 특성을 조절한 이토프라이드 염산염 함유 서방제제 | |
| KR102210422B1 (ko) | 신규한 용출 파라미터를 이용한 이토프라이드 함유 서방제제 | |
| KR102189200B1 (ko) | 용출 특성을 조절한 이토프라이드 염산염 함유 경구 투여 서방제제 | |
| KR101977050B1 (ko) | 1일 1회 경구투여하는 이토프라이드 염산염 함유 서방제제 | |
| US20220062183A1 (en) | Process for the manufacture of a tablet of rifaximin and tablet of rifaximin | |
| ZA200301866B (en) | Ion-strength independent sustained release pharmaceutical formulation. | |
| KR100798672B1 (ko) | 니자티딘을 포함하는 건식 과립물과 속효성 정제 및 그제조방법 | |
| WO2002011726A1 (fr) | Preparation solide hautement absorbable |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20190928 |